The $96 billion biotech Gilead will start testing a new version of the first effective coronavirus treatment, and it could make remdesivir available to vastly more patients (GILD)

The $96 billion biotech Gilead will start testing a new version of the first effective coronavirus treatment, and it could make remdesivir available to vastly more patients (GILD)

  • The biotech giant that developed the first effective coronavirus treatment is now looking to expand its impact.
  • Gilead Sciences CEO Daniel O’Day said Monday that the company would start testing an inhaled version of the antiviral drug remdes…

    Read More…

You May Also Like